Opinion
Video
HER2+ Breast Cancer Treatment Dynamics and Challenges
Health care professionals discuss the evolving landscape of HER2+ breast cancer treatments, delving into the complexities of the HER2CLIMB trial and strategies for third- and fourth-line interventions.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and Rugo discuss the HER2CLIMB-02 trial, summarizing its key findings and considering its place in the treatment algorithm. The trial, conducted in a different era, focused on a second-line setting, comparing T-DM1 (trastuzumab emtansine) plus or minus tucatinib in patients with HER2-positive breast cancer. The results demonstrated a significant improvement in median progression-free survival, especially in the subset with brain metastases. The trial’s unique aspects include a diverse patient population with varying lines of prior therapy.
Isaacs emphasizes the importance of survival data and expresses a preference for the HER2CLIMB regimen due to the established phase 3 trial. Rugo adds insights about the trial’s context, highlighting the changing treatment landscape and the need for access to effective therapies globally.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
